The success of life sciences companies will depend on products and services not yet found in a companies offerings in the next decade. Much of those products will be brought to companies through the merger and acquisitions of small to mid-sized companies. This panel discussed:
- When is the right time to get acquired?
- What is the survival rate of c-suite after an acquisition?
- Why is an acquisition better than a collaboration?
- What are the key issues in the due diligence process that can hurt the value of the deal?
- How does big pharma prepare for pricing negotiations and how can a smaller seller be prepared
- What types of steps can be taken to prepare a forecast that drives value negotiations
- How can this analysis be leverage in negotiating a collaborative or co-partner agreement
Presenters included:
- Todd Boudreau, Senior Counsel, Private Equity & Venture Capital Practice, Foley
- Dr. Ton Bunt, Senior Advisor, JSB Partners LP
- Sven Riethmueller, Of Counsel, Private Equity & Venture Capital, Foley
- David Schechner, Managing Director, Canaccord Adams
- Shane Senior, Managing Director, Crosstree Capital Partners Inc.
Related Insights
August 1, 2025
Foley Ignite
Is an IPO Window Opening for H2 2025?
Executive Summary The IPO market is showing encouraging signs of recovery in 2025, with 201 companies going public year-to-date compared…
August 1, 2025
Foley Viewpoints
Maryland Insurance Administration Proposes to Revise Regulation Governing Disclosures of Credit Scoring Use in Private Passenger Automobile Insurance Rating
The Maryland Insurance Administration recently proposed to revise a regulation regarding the use and disclosure of credit history in underwriting and rate making for personal automobile policies.
July 31, 2025
Foley Viewpoints
Tsunamis and the National Flood Insurance Program
On July 30, an 8.8 magnitude earthquake occurred off of Russia’s Eastern Kamchatka coast, subsequently triggering tsunami warnings in, among other places, Japan and Hawaii.